Thomas Doerr

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Optimizing the AV Delay in DDD Pacemaker Patients with High Degree AV Block: Mitral Valve Doppler Versus Impedance Cardiography

Michael Kindermann, GERD ERÖHLIG, Thomas Doerr et al. · Pacing and Clinical Electrophysiology · 1997 · 205 citations

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Sham Mailankody, Andrzej Jakubowiak, Myo Htut et al. · Journal of Clinical Oncology · 2020 · 121 citations

Clinical Immunology, Cell Therapy, Immunodeficiencies +26

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Tatsuo Ichinohe, Yoshiaki Kuroda, Shinichiro Okamoto et al. · Experimental Hematology and Oncology · 2015 · 18 citations · Full text

Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.

Paul G. Richardson, Albert Oriol Rocafiguera, Meral Beksaç et al. · Journal of Clinical Oncology · 2018 · 17 citations

Hematological Malignancy, Proteasome Inhibitors, Oncology +14